Group

The Americas Cancer Immunotherapy Market, as highlighted by MRFR, is projected to expand from USD 100.54 billion in 2024 to USD 118.27 billion by 2032, reflecting a CAGR of 15.32%. Monoclonal antibodies (mAbs) remain one of the most established and commercially successful segments, offering targeted action against specific cancer cell antigens. In the U.S., blockbuster drugs like trastuzumab and rituximab have paved the way for next-generation antibody-drug conjugates that combine targeting precision with potent cytotoxic agents. Canada’s healthcare systems are integrating biosimilar versions to improve affordability, while Latin American nations are gradually adopting mAbs through government-funded oncology programs. Beyond oncology treatment, mAbs are also being tested in adjuvant settings to prevent recurrence. The ability to engineer antibodies for enhanced immune engagement, combined with advances in manufacturing that reduce production costs, will ensure that monoclonal antibodies continue to be a mainstay in cancer immunotherapy strategies across the Americas.